Axicabtagene ciloleucel (CAR-T)
奕凯达 (Yescarta China)
A CAR-T cell therapy: your own immune T-cells are re-engineered to hunt the lymphoma, given as a one-time infusion.
At a glance
China price
¥1,200,000 per infusion
What this meansChecked against a primary or official source.
Source(s)
- 163.com/dy/article/JE0BDJK60552IJOG.html
Secondary source (media / community / commercial) - xueqiu.com/4097176039/338291915
Secondary source (media / community / commercial)
Last checked2026-09-08
Noteslist price
NRDL (national insurance)
Not in NRDL — self-pay; some commercial/city insurance plans contribute.
Regulatory status
NMPA approved (2021); not in NRDL
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
International comparison
US/EU list price approx USD 400,000+ per infusion
What this meansReported information that has not yet been independently confirmed.
SourceNo independent source on file.
NotesReported comparison, not independently verified.
What it treats
Relapsed/refractory large B-cell lymphoma after 2+ lines of therapy.
How it is accessed in China
- Certified tertiary hospitals (~100+ centers)
- Outcome-based payment plan: up to RMB 600k refund if no CR
One of 6 CAR-T products approved in China. Price gap ~2.4x at list; China offers pay-for-performance plan.
Related treatments
Sources & verification
- 163.com/dy/article/JE0BDJK60552IJOG.html — Secondary source (media / community / commercial)
- xueqiu.com/4097176039/338291915 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Axicabtagene ciloleucel (CAR-T). Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.